A pharmacokinetic-pharmacodynamic/toxicodynamic model framework for PARP inhibitor combination therapy with DNA-damaging chemotherapeutics

  • Cancer Chemother Pharmacol. 2026 Jan 20;96(1):11. doi: 10.1007/s00280-025-04862-w.
Li Chen  1 ,  Ronald W Bucher  1 ,  Derek W Bartlett  2
Affiliations
  • 1. Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • 2. Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. [email protected].
PMID: 41554954 DOI: 10.1007/s00280-025-04862-w
Keywords
Dose optimization; PARP inhibitor combination therapy; Resistance; Temozolomide chemotherapy; Time to progression; Virtual patients.
Products